Cargando...
The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
BACKGROUND: Hypomethylating agents (HMAs), such as decitabine (DAC), are currently used as first-line therapy for patients with high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) not eligible for standard chemotherapies. Exacerbation of thrombocytopenia is one of the prev...
Guardado en:
| Publicado en: | Cancer Manag Res |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735651/ https://ncbi.nlm.nih.gov/pubmed/31564981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S213931 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|